ProCE Banner Activity

Management of Immunotherapy-Related Adverse Events in Solid Tumors: Highlights and Answers to Your Frequently Asked Questions

Clinical Thought

Read this commentary with insights from advanced practice providers covering strategies for the management of AEs associated with immune checkpoint inhibitor monotherapy and combination therapy regimens in patients with solid tumors including answers to frequently-asked questions.

Released: May 06, 2025

Expiration: November 05, 2025

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Clinical Care Options, LLC (CCO) and Practicing Clinicians Exchange (PCE).

ProCE Banner

Supporters

Supported by educational grants from Bristol Myers Squibb and Merck Sharp & Dohme LLC.

Bristol Myers Squibb

Merck Sharp & Dohme, LLC

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange, LLC

ProCE Banner

Disclosure

Primary Author

Suzanne McGettigan, MSN, CRNP, AOCN, ANP-BC: consultant/advisor/speaker: Bristol Myers Squibb, Pfizer, Regeneron.